176 related articles for article (PubMed ID: 31251364)
1. Proton pump inhibitor use and progression to major adverse renal events: a competing risk analysis.
Grant CH; Gillis KA; Lees JS; Traynor JP; Mark PB; Stevens KI
QJM; 2019 Nov; 112(11):835-840. PubMed ID: 31251364
[TBL] [Abstract][Full Text] [Related]
2. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
Hart E; Dunn TE; Feuerstein S; Jacobs DM
Pharmacotherapy; 2019 Apr; 39(4):443-453. PubMed ID: 30779194
[TBL] [Abstract][Full Text] [Related]
3. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and outcomes of proton pump inhibitor associated hypomagnesemia in chronic kidney disease.
Hughes J; Y Y Chiu D; Kalra PA; Green D
PLoS One; 2018; 13(5):e0197400. PubMed ID: 29799851
[TBL] [Abstract][Full Text] [Related]
5. Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease.
Klatte DCF; Gasparini A; Xu H; de Deco P; Trevisan M; Johansson ALV; Wettermark B; Ärnlöv J; Janmaat CJ; Lindholm B; Dekker FW; Coresh J; Grams ME; Carrero JJ
Gastroenterology; 2017 Sep; 153(3):702-710. PubMed ID: 28583827
[TBL] [Abstract][Full Text] [Related]
6. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
Kidney Int; 2017 Jun; 91(6):1482-1494. PubMed ID: 28237709
[TBL] [Abstract][Full Text] [Related]
7. Duration and dosing of Proton Pump Inhibitors associated with high incidence of chronic kidney disease in population-based cohort.
Rodríguez-Poncelas A; Barceló MA; Saez M; Coll-de-Tuero G
PLoS One; 2018; 13(10):e0204231. PubMed ID: 30332411
[TBL] [Abstract][Full Text] [Related]
8. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.
Xie Y; Bowe B; Li T; Xian H; Balasubramanian S; Al-Aly Z
J Am Soc Nephrol; 2016 Oct; 27(10):3153-3163. PubMed ID: 27080976
[TBL] [Abstract][Full Text] [Related]
9. Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients.
Lee HJ; Lee H; Oh SH; Park J; Park S; Jeon JS; Noh H; Han DC; Kwon SH
PLoS One; 2018; 13(9):e0203878. PubMed ID: 30212538
[TBL] [Abstract][Full Text] [Related]
10. Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKD-REIN cohort study.
Liabeuf S; Lambert O; Metzger M; Hamroun A; Laville M; Laville SM; Frimat L; Pecoits-Filho R; Fouque D; Massy ZA; Jacquelinet C; Stengel B;
Br J Clin Pharmacol; 2021 Jul; 87(7):2967-2976. PubMed ID: 33368448
[TBL] [Abstract][Full Text] [Related]
11. Non-indicated initiation of proton pump inhibitor and risk of adverse outcomes in patients with underlying chronic kidney disease: a nationwide, retrospective, cohort study.
Kim SG; Cho JM; Han K; Joo KW; Lee S; Kim Y; Cho S; Huh H; Kim M; Kang E; Kim DK; Park S
BMJ Open; 2024 Jan; 14(1):e078032. PubMed ID: 38286693
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease.
Arora P; Gupta A; Golzy M; Patel N; Carter RL; Jalal K; Lohr JW
BMC Nephrol; 2016 Aug; 17(1):112. PubMed ID: 27487959
[TBL] [Abstract][Full Text] [Related]
13. Urinary neutrophil gelatinase-associated lipocalin may aid prediction of renal decline in patients with non-proteinuric Stages 3 and 4 chronic kidney disease (CKD).
Smith ER; Lee D; Cai MM; Tomlinson LA; Ford ML; McMahon LP; Holt SG
Nephrol Dial Transplant; 2013 Jun; 28(6):1569-79. PubMed ID: 23328709
[TBL] [Abstract][Full Text] [Related]
14. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression.
Cholin L; Ashour T; Mehdi A; Taliercio JJ; Daou R; Arrigain S; Schold JD; Thomas G; Nally J; Nakhoul NL; Nakhoul GN
BMC Nephrol; 2021 Jul; 22(1):264. PubMed ID: 34266395
[TBL] [Abstract][Full Text] [Related]
15. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.
Seethapathy H; Zhao S; Chute DF; Zubiri L; Oppong Y; Strohbehn I; Cortazar FB; Leaf DE; Mooradian MJ; Villani AC; Sullivan RJ; Reynolds K; Sise ME
Clin J Am Soc Nephrol; 2019 Dec; 14(12):1692-1700. PubMed ID: 31672794
[TBL] [Abstract][Full Text] [Related]
16. Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.
Koye DN; Magliano DJ; Reid CM; Jepson C; Feldman HI; Herman WH; Shaw JE
Am J Kidney Dis; 2018 Nov; 72(5):653-661. PubMed ID: 29784612
[TBL] [Abstract][Full Text] [Related]
17. Sex Differences in the Progression of CKD Among Older Patients: Pooled Analysis of 4 Cohort Studies.
Minutolo R; Gabbai FB; Chiodini P; Provenzano M; Borrelli S; Garofalo C; Bellizzi V; Russo D; Conte G; De Nicola L;
Am J Kidney Dis; 2020 Jan; 75(1):30-38. PubMed ID: 31409508
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Proton Pump Inhibitor Use on the Course of Kidney Function in Patients with Chronic Kidney Disease Stages G3a to G4.
Giusti S; Lin Y; Sogbetun F; Nakhoul N; Liu S; Shi L; Batuman V
Am J Med Sci; 2021 Nov; 362(5):453-461. PubMed ID: 34033809
[TBL] [Abstract][Full Text] [Related]
19. PPIs and kidney disease: from AIN to CKD.
Moledina DG; Perazella MA
J Nephrol; 2016 Oct; 29(5):611-6. PubMed ID: 27072818
[TBL] [Abstract][Full Text] [Related]
20. The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: a cross-sectional study.
Misra PS; Alam A; Lipman ML; Nessim SJ
BMC Nephrol; 2015 Aug; 16():136. PubMed ID: 26268579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]